Lafamme (Dienogest, Estradiol Valerate)

Lafamme, a combined oral contraceptive, is indicated for conditions related to reproductive hormone regulation.

• Contraception: Prevents unintended pregnancy by suppressing ovulation and altering cervical mucus.
• Menstrual cycle regulation: Helps achieve more predictable menstrual bleeding patterns in women with irregular cycles.
• PCOS symptom management: Improves androgen levels and menstrual regularity in women with polycystic ovary syndrome.

• Lafamme combines estradiol valerate, an estrogen, with dienogest, a progestogen. Estradiol provides negative feedback to the hypothalamic‑pituitary axis, reducing follicle‑stimulating hormone release, while dienogest suppresses the luteinizing hormone surge, preventing ovulation. The progestogen also thickens cervical mucus and induces endometrial changes that hinder implantation. Estradiol further stabilizes the endometrial lining, supporting regular withdrawal bleeding and contributing to the hormonal balance required for contraceptive efficacy.

Lafamme may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild gastrointestinal upset, often transient.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: discomfort or swelling of breast tissue.
• Weight gain: modest fluid‑related increase.
• Mood changes: irritability or emotional fluctuations.
• Spotting or irregular bleeding: breakthrough bleeding during early cycles.

Serious or Rare Side Effects

• Deep vein thrombosis: blood clot formation in deep veins.
• Pulmonary embolism: clot migration to lung vessels.
• Stroke: cerebrovascular event due to clot or hemorrhage.
• Myocardial infarction: heart attack risk in susceptible individuals.
• Severe hypertension: sudden high blood pressure episodes.
• Hepatic adenoma: rare benign liver tumor.

When prescribing Lafamme, clinicians should consider several precautionary measures to ensure patient safety.

• Contraindications: Avoid in women with a history of thromboembolic disorders, estrogen‑dependent tumors, or uncontrolled hypertension.
• Smoking: Do not prescribe to women over 35 who smoke, due to increased cardiovascular risk.
• Medication review: Assess concurrent use of enzyme‑inducing drugs that may reduce contraceptive effectiveness.
• Pregnancy testing: Confirm negative pregnancy test before initiation.
• Breastfeeding: Use only if benefits outweigh risks, as estrogen may affect milk production.
• Store at room temperature: keep below 25°C in the original packaging, protect from moisture and light.

Lafamme can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, phenytoin): may cause contraceptive failure.
• Anticoagulants (warfarin): increased risk of thrombosis.
• SSRIs with QT‑prolongation potential: may heighten cardiac event risk.

Moderate Interactions (Monitor Closely)

• Antiepileptics (carbamazepine): may lower hormone levels, monitor cycle control.
• Antifungals (ketoconazole): may raise hormone concentrations, watch for side effects.
• Herbal supplements (St. John’s wort): may decrease effectiveness, advise caution.